SCHEMBL4667258

SCHEMBL4667258

CCN1C(=CC(C)=O)Sc2cc(OC)ccc21

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 6/20 0.81
HSD17B10 Q99714 5/20 0.81
MAPT P10636 5/20 0.81
ALDH1A1 P00352 5/20 0.81
CLK1 P49759 4/20 0.81
HPGD P15428 4/20 0.81
CSNK1E P49674 3/20 0.81
CLK3 P49761 3/20 0.81
DYRK1B Q9Y463 3/20 0.81
HTT P42858 3/20 0.81
PIM1 P11309 2/20 0.81
CSNK1D P48730 2/20 0.81
CSNK1G2 P78368 2/20 0.81
MAP3K19 Q56UN5 2/20 0.81
PIM3 Q86V86 2/20 0.81
CSNK1G3 Q9Y6M4 2/20 0.81
NPSR1 Q6W5P4 2/20 0.81
CLK2 P49760 2/20 0.81
CLK4 Q9HAZ1 2/20 0.81
MEN1 O00255 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18166902 1.00 DYRK1A (0.81) DYRK1AHSD17B10MAPTALDH1A1CLK1
SCHEMBL4667255 1.00 DYRK1A (0.81) DYRK1AHSD17B10MAPTALDH1A1CLK1
SCHEMBL2977826 0.90 DYRK1A (1.00) DYRK1AHSD17B10MAPTALDH1A1CLK1
SCHEMBL2977830 0.90 DYRK1A (1.00) DYRK1AHSD17B10MAPTALDH1A1CLK1
SCHEMBL18416400 0.83 CLK1 (0.64) DYRK1AHSD17B10MAPTALDH1A1CLK1
SCHEMBL14306939 0.81 MAPT (0.54) DYRK1AHSD17B10MAPTALDH1A1CLK1
SCHEMBL14281090 0.79 MAPT (0.52) DYRK1AHSD17B10MAPTALDH1A1CLK1
SCHEMBL19897109 0.79 SNCA (0.55) DYRK1AHSD17B10MAPTALDH1A1CLK1
SCHEMBL24718937 0.79 MAPT (1.00) DYRK1AHSD17B10MAPTALDH1A1CLK1
SCHEMBL4018924 0.79 DYRK1A (0.80) DYRK1AHSD17B10MAPTALDH1A1CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372309-A1 ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST KYOTO UNIVERSITY (JP) 2023-11-23 US disclosed
EP-4218818-A1 ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST Kyoto University (JP) 2023-08-02 EP disclosed
EP-3085698-B1 PAIN-RELATED COMPOUND AND MEDICINAL COMPOSITION UNIV KYOTO (JP) 2019-11-13 EP disclosed
US-9745275-B2 Pain-related compound and medical composition KYOTO UNIVERSITY (JP) 2017-08-29 US disclosed
US-20170029389-A1 PAIN-RELATED COMPOUND AND MEDICAL COMPOSITION KYOTO UNIVERSITY (JP) 2017-02-02 US disclosed
EP-3085698-A1 PAIN-RELATED COMPOUND AND MEDICINAL COMPOSITION Kyoto University (JP) 2016-10-26 EP disclosed
US-20080193700-A1 Metal Chelates and Their Use in Optical Recording Media Having High Storage Capacity CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2008-08-14 US disclosed
EP-1743333-A1 METAL CHELATES AND THEIR USE IN OPTICAL RECORDING MEDIA HAVING HIGH STORAGE CAPACITY CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement (CH) 2007-01-17 EP disclosed
WO-2005106868-A1 METAL CHELATES AND THEIR USE IN OPTICAL RECORDING MEDIA HAVING HIGH STORAGE CAPACITY CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372309-A1 ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST ADRA2A, ADRB2, ADRA2B DYRK1A 910/4885HSD17B10 2460/4885MAPT 2183/4885
US-20170029389-A1 PAIN-RELATED COMPOUND AND MEDICAL COMPOSITION OPRL1, TRPV1, P2RY11 DYRK1A 2941/4885HSD17B10 1797/4885MAPT 672/4885
US-20080193700-A1 Metal Chelates and Their Use in Optical Recording Media Having High Storage Capacity TMCO1, KCNN3, CACNA1F DYRK1A 4133/4885HSD17B10 4629/4885MAPT 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.